May 14, 2026 10:55AM
May 14, 2026 10:55AM
May 14, 2026 09:15AM
Mar 2, 2026 07:00AM
Feb 3, 2026 08:32AM
Feb 3, 2026 08:30AM
Jan 16, 2026 11:18AM THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle
Jan 15, 2026 08:32AM
Jan 15, 2026 08:30AM
Dec 24, 2025 06:00AM
Dec 24, 2025 06:00AM
Dec 15, 2025 10:54AM
Nov 19, 2025 08:00AM
Nov 19, 2025 08:00AM GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
Nov 14, 2025 09:00AM
Aug 14, 2025 04:05PM
Nov 14, 2024 04:00PM
Aug 14, 2024 04:05PM
Jun 27, 2024 09:17AM
Jun 27, 2024 09:15AM
May 15, 2024 05:00PM GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Mar 26, 2024 05:00PM
Dec 4, 2023 09:30AM
Nov 1, 2023 09:00AM
Aug 7, 2023 09:00AM
May 15, 2023 05:00PM
Mar 30, 2023 05:00PM
Feb 2, 2023 09:47AM GT Biopharma (GTBP) Issues Open Letter to Shareholders Detailing Recent Activities
Feb 2, 2023 09:46AM
Aug 30, 2022 06:05PM
Aug 30, 2022 06:00PM
Jan 20, 2022 07:30AM
Jan 6, 2022 04:30PM
Dec 8, 2021 07:32AM
Dec 8, 2021 07:30AM GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021
Nov 30, 2021 07:30AM
Nov 24, 2021 04:05PM
Nov 10, 2021 04:10PM
Nov 8, 2021 07:30AM
Sep 20, 2021 07:00AM
Sep 15, 2021 07:08AM
Sep 15, 2021 07:00AM GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021
Sep 13, 2021 07:00AM
Sep 9, 2021 07:00AM
Sep 8, 2021 12:28PM
Aug 23, 2021 07:00AM
Aug 13, 2021 07:30AM
Aug 6, 2021 08:00AM
Aug 3, 2021 07:00AM GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
Jul 28, 2021 08:02AM

322,348 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All